Financial Performance - The company's operating revenue for Q3 2025 was ¥342,707,426.71, a decrease of 20.63% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2025 was ¥5,115,431.80, an increase of 109.11% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥105,723.49, up 100.17% from the previous year[5]. - Total operating revenue for the current period was ¥1,102,095,711.13, a decrease of 16.5% compared to ¥1,320,029,736.34 in the previous period[24]. - Total operating costs decreased to ¥1,065,770,911.06, down 17.9% from ¥1,298,282,175.55 in the previous period[24]. - Net profit for the current period was ¥10,207,252.28, a significant recovery from a net loss of ¥53,179,196.56 in the previous period[25]. - The total comprehensive income for the current period was ¥10,207,252.28, recovering from a loss of ¥53,179,196.56 in the previous period[25]. - Basic and diluted earnings per share were both ¥-0.0017, an improvement from ¥-0.1026 in the previous period[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥171,758,891.35, a significant increase of 707.47%[12]. - The company reported a net cash flow from operating activities of ¥171,758,891.35, compared to a negative cash flow of ¥28,274,515.34 in the previous period[26]. - The net cash flow from investing activities improved by 45.13%, amounting to -¥26,617,005.57, as the acquisition of long-term assets decreased[13]. - Net cash flow from investing activities was -$26.62 million, an improvement from -$48.50 million in the previous period[27]. - The net cash flow from financing activities was -¥227,607,418.10, a decrease of 128.75% primarily due to dividend payments[13]. - The net cash flow from financing activities was -$227.61 million, worsening from -$99.50 million year-over-year[27]. Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,430,758,449.35, down 7.34% from the end of the previous year[5]. - The total assets decreased to ¥2,430,758,449.35 from ¥2,623,334,426.70, a reduction of approximately 7.3%[21]. - Total current assets decreased to ¥1,843,699,090.36 from ¥1,998,640,598.09, a reduction of approximately 7.8%[19]. - Total liabilities decreased to ¥760,428,114.90 from ¥802,997,927.54, a decline of about 5.3%[21]. - The company’s total equity attributable to shareholders decreased by 4.85% to ¥1,577,756,499.98 compared to the end of the previous year[5]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,745[15]. - Shanghai Lanwei Investment Co., Ltd. holds 37.34% of shares, totaling 149,554,017 shares[15]. - The company has a total of 1,996,100 shares in the repurchase account, accounting for 0.50% of the total share capital[16]. - The number of restricted shares held by Sun Linjie is 4,805,680, all of which are executive lock-up shares[17]. - The company has no changes in the top 10 shareholders due to margin trading or securities lending[16]. Expenses and Costs - Research and development expenses were ¥38,357,166.74, down 14.6% from ¥44,916,908.61 in the previous period[24]. - The company achieved a gross profit margin of approximately 3.3% for the current period, compared to a negative margin in the previous period[24]. - The company recorded a significant decrease in credit impairment losses, which were ¥-13,501,833.70, compared to ¥-30,771,031.56 in the previous period[25]. - The company reported a significant decrease in financial expenses, down 55.71% to ¥2,193,528.37 due to reduced bank loans[11]. Audit Information - The company did not undergo an audit for the third quarter financial report[28].

Core Points - Lanwei Medical announced the convening of the fourth board meeting and the first extraordinary shareholders' meeting in 2025 to review and approve the proposal for amending and supporting procedural rules and handling business registration changes [1] - The company has completed the business registration changes and the filing of the Articles of Association, obtaining a new business license issued by the Shanghai Municipal Market Supervision Administration [1]

证券代码：301060 证券简称：兰卫医学 公告编号：2025-038 4、经营范围：许可项目：医疗服务；检验检测服务；道路货物运输（不含危险货 物）。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相 关部门批准文件或许可证件为准）一般项目：医学研究和试验发展；环境保护监测；计 量技术服务；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；货物 进出口；技术进出口；细胞技术研发和应用；软件开发；软件销售；人工智能应用软件 开发；计算机软硬件及辅助设备批发；计算机软硬件及辅助设备零售；信息系统集成服 务；计算机系统服务；信息系统运行维护服务；信息技术咨询服务；国内货物运输代理； 上海兰卫医学检验所股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）分别于 2025 年 8 月 22 日、 2025 年 9 月 19 日召开了第四届董事会第四次会议和 2025 年第一次临时股东大会，审 议通过了《关于修订<公司章程>及配套议事规则 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-037 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海兰卫医学检验所股 份有限公司章程》（以下简称"《公司章程》"）等有关规定，经公司总经理提名、董事会 提名委员会资格审查通过，董事会同意聘任吴川江先生（简历详见附件）为公司副总经 理，任期自第四届董事会第六次会议通过之日起至公司第四届董事会届满之日止。 吴川江先生具备担任公司副总经理的履职能力和任职资格，符合《公司法》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、 规范性文件及《公司章程》的规定。 特此公告。 上海兰卫医学检验所股份有限公司 董事会 2025 年 9 月 29 日 上海兰卫医学检验所股份有限公司 关于聘任公司副总经理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日召开 了第四届董事会第六次会议，审议通过了《关于聘任公司副总经理的议案》。 附件： 个人简历 吴川江先生：1975 年 5 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-036 上海兰卫医学检验所股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届董事会第六次会议 于 2025 年 9 月 29 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的通知 已于 2025 年 9 月 24 日以邮件形式通知全体董事。会议由公司董事长曾伟雄先生主持， 本次会议应出席董事 7 人，实际出席董事 7 人。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》《上海兰卫医学检验所股份有限公司章程》规定，会议合法、 有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于聘任公司副总经理的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《关于聘任公 司副总经理的公告》（公告编号：2025-037）。 表决结果：同意 7 票，反对 0 票，弃权 0 ...

Core Viewpoint - Lanwei Medical (301060.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges despite a positive cash flow from operating activities [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 was 759.39 million yuan, a decrease of 14.50% compared to the same period last year [2]. - The net profit attributable to shareholders was -5.78 million yuan, reflecting a year-on-year decrease of 137.08% [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -7.64 million yuan, down 170.04% year-on-year [2]. - The net cash flow from operating activities was 37.23 million yuan, a significant improvement from -48.14 million yuan in the previous year, marking a 177.35% increase [2]. Future Projections - For 2023 and 2024, the projected operating revenues are 1.67 billion yuan and 1.74 billion yuan, respectively, with net profits expected to remain negative at -142 million yuan and -109 million yuan [3]. - The net profit after deducting non-recurring gains and losses for 2023 and 2024 is projected to be -152 million yuan and -109 million yuan, respectively [3]. Initial Public Offering (IPO) Details - Lanwei Medical raised a total of 200 million yuan from its IPO, with a net amount of 139 million yuan after deducting issuance costs, which was 67.4 million yuan less than originally planned [4]. - The funds raised are intended for laboratory upgrades, information platform construction, and medical testing R&D center projects [4].

Core Viewpoint - Lanwei Medical (301060) announced the election of Ms. Xiong Chang as the employee representative director of the fourth board of directors during the fifth ninth employee representative assembly held on September 19, 2025 [1] Summary by Category - **Company Announcement** - Lanwei Medical held its fifth ninth employee representative assembly on September 19, 2025 [1] - Ms. Xiong Chang was democratically elected as the employee representative director of the fourth board of directors [1]

Group 1 - The company Lanwei Medical (SZ 301060) held its fourth fifth board meeting on September 19, 2025, to discuss the election of Ms. Xiong Chang as a member of the strategic committee [1] - For the first half of 2025, the revenue composition of Lanwei Medical was 51.41% from commercial activities and 48.59% from services [1] - As of the report date, Lanwei Medical has a market capitalization of 3.8 billion yuan [1]

一、董事会会议召开情况 证券代码：301060 证券简称：兰卫医学 公告编号：2025-034 上海兰卫医学检验所股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 本议案无需提交公司股东大会审议。 三、备查文件 1、第四届董事会第五次会议决议。 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届董事会第五次会议 于 2025 年 9 月 19 日在公司会议室以现场结合通讯会议方式召开。因事项紧急，召开本 次会议的通知于 2025 年 9 月 19 日现场通知全体董事，全体董事会成员同意豁免本次会 议提前通知期限要求。会议由公司董事长曾伟雄先生主持，本次会议应出席董事 6 人， 实际出席董事 6 人。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 《上海兰卫医学检验所股份有限公司章程》规定，会议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于补选熊畅女士为公司第四届董事会战略委员会委员的议案》 具体内容详见公司同日披露于巨潮 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-035 上海兰卫医学检验所股份有限公司 关于公司选举职工代表董事暨补选董事会战略委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开 了 2025 年第一次临时股东大会，审议通过了《关于修订<公司章程>及配套议事规则并 办理工商变更登记的议案》。根据修订后的《上海兰卫医学检验所股份有限公司章程》 （以下简称"《公司章程》"），公司董事会设职工代表董事一名，职工代表董事由公司职 工通过职工代表大会民主选举产生。现将有关事项公告如下： 一、关于选举公司职工代表董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《公司章程》等有关规定， 公司于 2025 年 9 月 19 日召开了第五届第九次职工代表大会，经公司职工代表大会民主 选举，由熊畅女士（简历详见附件）担任公司第四届董事会职工代表董事。熊畅女士将 与公司现任第四届董事会非职工代表董事共同组成公司第四届董事会，任期自职工代表 大会 ...